Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Stress Disorders, Post-Traumatic 1Sleep Initiation and Maintenance Disorders 1Sleep Disorders, Circadian Rhythm 1Sleep Deprivation 1REM Sleep Behavior Disorder 1Psychological Well-Being 1Pain 1Leukemia 1Idiopathic Hypersomnia 1Depression 1Combat Disorders 1Chronobiology Disorders 1Cancer Pain 1Anxiety Disorders 1Alzheimer Disease 1

Interventions

Cytarabine 21Imatinib Mesylate 20venetoclax 16Azacitidine 16nilotinib 15Cyclophosphamide 15fludarabine 13Dasatinib 12blinatumomab 10Rituximab 10quizartinib 7Gemtuzumab 7Daunorubicin 7ruxolitinib 6Drug Therapy 6Clofarabine 6Bendamustine Hydrochloride 6AP 1903 reagent 6ponatinib 5fludarabine phosphate 5Whole-Body Irradiation 5Vincristine 5Mycophenolic Acid 5Methotrexate 5Granulocyte Colony-Stimulating Factor 5Dexamethasone 5vosaroxin 4revumenib 4rasburicase 4forodesine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia × Propofol × Clear all
NCT01326078 2014-03-26

Use of Lipid Emulsion or Nanoemulsion of Propofol on Children Undergoing Ambulatory Invasive Procedures.

CristĂĄlia Produtos QuĂ­micos FarmacĂȘuticos Ltda.

Phase 2/3 Withdrawn
Other hematologic neoplasm

Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡